Stock Report

Download full stock data and analysis for free Last Updated: 23-Oct-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Krystal Biotech (KRYS) Peer Comparison

Stock Card factsheet share-fund-plan-icon

$320.13

up-down-arrow $-2.04 (-0.63%)

As on 22-Oct-2026 16:00EDT

Market cap

info icon

$9,370 Mln

Revenue (TTM)

info icon

$440 Mln

P/E Ratio

info icon

39.7

P/B Ratio

info icon

7.4

Div. Yield

info icon

0 %

Edit peer-selector-edit
Krystal Biotech (KRYS) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Market cap ($ Mln)
 9,370 17,263 14,822 15,419 13,829
Revenue ($ Mln)
 440 2,782 1,054 2,436 1,664
Net Profit ($ Mln)
 241.47 491.50 755.85 860.62 413.60
Net Margin (%)
 54.82 17.67 71.69 35.33 24.86
RoE (%)
 18.73 110.09 -- 42.98 430.03
Price to Earnings
 39.67 36.32 17.26 19.63 35.63
Price-To-Book
 7.44 39.70 8.91 7.82 88.91

Income Statement ($ Mln)

Krystal Biotech (KRYS) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Operating Revenue arrow
440.48 2,782.29 1,054.37 2,435.92 1,663.74
Cost of Revenue arrow
29.34 1,982.07 103.47 85.67 292.42
Gross Profit arrow
360.36 760.62 588.53 2,236.43 1,167.84
Operating Expenses arrow
213.23 216.81 841.45 1,378.74 440.53
Operating Profit (EBIT) arrow
197.92 583.40 109.45 971.51 930.79
Other Income arrow
0.00 0.00 0.00 0.00 0.00
Profit before Tax arrow
226.62 598.92 101.11 1,035.47 583.34
Provision for Tax arrow
-14.85 107.42 -654.74 174.84 169.74
Profit after Tax (Net Income) arrow
241.47 491.50 755.85 860.62 413.60
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Consolidated Profit arrow
0.00 0.00 0.00 0.00 0.00

Liabilities ($ Mln)

Krystal Biotech (KRYS) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Shareholder's Funds arrow
1,359.13 433.86 1,435.90 1,843.76 143.54
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Non-Current Liabilities arrow
14.13 187.89 384.48 288.55 2,089.43
Current Liabilities arrow
127.40 1,435.43 464.70 361.93 344.44
Total Liabilities arrow
1,333.79 1,975.47 1,302.02 2,844.42 2,525.32

Assets ($ Mln)

Krystal Biotech (KRYS) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Non-Current Assets arrow
441.00 1,006.90 895.24 1,243.41 1,644.38
Current Assets arrow
1,059.65 1,050.29 1,389.84 1,250.82 933.02
Total Assets arrow
1,333.79 1,975.47 1,302.02 2,844.42 2,525.32
Total Debt* arrow
8.85 144.11 449.89 165.93 2,146.65
Net Current Assets arrow
932.25 -385.14 925.52 888.90 588.59

Cashflow ($ Mln)

Krystal Biotech (KRYS) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Cash From Operating Activities arrow
200.87 713.22 51.77 884.27 651.56
Cash Flow from Investing Activities arrow
-58.42 -31.14 -8.15 350.44 -545.81
Cash from Financing Activities arrow
8.71 -860.39 34.89 -969.59 -85.17
Net Cash Inflow / Outflow arrow
-- -- -- -- --

Ratios

Profitability Ratios

 Krystal Biotech (KRYS) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
ROCE (%) arrow
18.77 57.43 -30.01 32.82 15.61
ROE (%) arrow
18.73 110.09 163.18 42.98 430.03
ROA (%) arrow
16.93 15.64 31.68 29.32 16.19
EBIT Margin (%) arrow
48.43 21.13 5.73 41.82 36.28
Net Margin (%) arrow
54.82 17.67 71.69 35.33 24.86
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Krystal Biotech (KRYS) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Revenue Growth (%) arrow
22.63 24.67 114.85 9.23 41.15
EBIT Growth (%) arrow
22.66 18.70 136.39 29.37 -14.99
Net Profit Growth (%) arrow
64.57 17.50 378.76 42.89 -25.78
EPS Growth (%) arrow
62.67 26.84 353.27 50.42 -23.48
Book Value Growth (%) arrow
26.74 164.02 816.12 -0.70 -55.81

Valuation Ratios

 Krystal Biotech (KRYS) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Price / Earnings arrow
36.05 36.06 -59.76 15.79 24.99
Price / Book Value arrow
6.05 35.44 -80.42 5.72 162.23
Dividend Yield (%) arrow
-- -- -- -- --
EV/EBITDA arrow
33.49 27.88 -121.54 12.44 17.31
Market Cap ($ Cr) arrow
-- -- -- -- --

Solvency Ratios

 Krystal Biotech (KRYS) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Debt to Equity arrow
0.00 0.00 0.27 0.00 13.50
Short term debt to equity ratio arrow
0.00 0.06 0.05 0.00 1.46
Current Ratio arrow
8.32 0.73 2.99 3.46 2.71
Quick Ratio arrow
7.96 0.73 2.32 3.38 2.31
Interest Coverage arrow
-- -- 1.62 -- 29.73

Operating Efficiency Ratios

 Krystal Biotech (KRYS) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Debtors to sales (%) arrow
31.48 15.88 21.25 13.74 27.40
Asset Turnover arrow
0.31 0.89 0.44 0.83 0.65
Receivable days arrow
108.96 50.42 85.52 43.48 98.04
Inventory Days arrow
425.15 -- 1,056.70 96.17 254.12
Payable days arrow
52.19 6.26 331.01 147.97 24.86
Cash Conversion Cycle arrow
481.92 -- 811.21 -8.32 327.29
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...